Abstract

BackgroundWomen with active chronic rheumatic inflammatory conditions (RA, PsA, AxSpA) often face uncertainty regarding the safety of the use of biologics during breastfeeding.1 Limited and non-validated data exist on the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study
Astrid Van Tubergen ... Thomas W Hale
Annals of the Rheumatic Diseases | VOL. 76
Astrid Van Tubergen, et. al.Astrid Van Tubergen ... Thomas W Hale
16 Aug 2017
Access to the medical literature
P Ellis ... J L Mcgowan
Canadian Medical Association Journal | VOL. 177
P Ellis, et. al.P Ellis ... J L Mcgowan
17 Jul 2007
Evaluating Transfer of Certolizumab Pegol and Polyethylene Glycol into Breast Milk [28J
Frauke Förger ... Thomas W Hale
Obstetrics & Gynecology | VOL. 129
Frauke Förger, et. al.Frauke Förger ... Thomas W Hale
01 May 2017
Evaluating Transfer of Certolizumab Pegol into Breast Milk: Results from CRADLE, a Prospective, Postmarketing, Multicenter Pharmacokinetics Study
Astrid Van Tubergen ... Frauke Förger
American Journal of Gastroenterology | VOL. 111
Astrid Van Tubergen, et. al.Astrid Van Tubergen ... Frauke Förger
01 Oct 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers